San Francisco Marriott Marquis
Yerba Buena Ballroom, Salon 8, Lower B2 Level
780 Mission Street
San Francisco, CA 94103
6:30 PM: Registration, iPad Survey, and Dinner
7:00 PM: Master Class 1—Current Management of Advanced HCC: Identifying Opportunities to Address Unmet Need
7:15 PM: Master Class 2 & Practicum—Systemic Targeted Therapy for Advanced HCC: Choosing Among Current and Emerging Options Across Lines of Therapy
7:40 PM: Master Class 3 & Practicum—Understanding & Realizing the Full Potential of Immuno-Oncology in Advanced HCC
8:05 PM: Master Class 4—The Next Frontier: Examining Ongoing Clinical Trials Combining Therapies and Treatment Modalities in HCC
8:20 PM: Reflections and Conclusion, Final Q&A
8:30 PM: Adjourn
The treatment landscape for intermediate and advanced hepatocellular carcinoma (HCC) is rapidly evolving with new approved systemic therapies and additional agents poised to enter the armamentarium. Combinations of agents or of systemic therapy with other treatment modalities are the next frontiers in the treatment of HCC. The advent of new and emerging treatment options has resulted in increasingly complex clinical decisions for the management of HCC.
Join us for a CME-certified dinner symposium where experts will review the latest clinical data on approved and emerging systemic targeted therapies and immuno-oncology agents for the treatment of HCC, explain the underlying rationale for their therapeutic use in HCC, and provide practical strategies for safely and effectively incorporating new and evolving agents into clinical practice.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of oncologists, interventional radiologists, hepatologists, and other clinicians involved in the management of patients with hepatocellular carcinoma.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.
Release and Expiration Date: January 18, 2018
Time to Complete: 90 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York
Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Richard S. Finn, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, California
Marie Becker, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This educational activity is supported through medical education grants from Bristol-Myers Squibb, Eisai Inc., and Exelixis, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.